- Market News
Daiichi Sankyo releases new generic formulation for sustained cancer pain treatment13 Sep 2019
New formulation of oxycodone hydrochloride contains the narcotic antagonist naloxone in order to prevent abuse.
Daiichi Sankyo has launched a new generic formulation of oxycodone hydrochloride hydrate extended release tablets for sustained cancer pain treatment in Japan: Oxycodone Extended Release Tablets 5 mg, 10 mg, 20 mg and 40 mg NX “Daiichi Sankyo”.
The new formulation of oxycodone hydrochloride, a strong opioid analgesic providing relief of moderate to severe pain in various types of cancer, contains the narcotic antagonist naloxone in order to prevent abuse.
It is manufactured from drug substance to formulation solely by Daiichi Sankyo’s subsidiary in Japan, Daiichi Sankyo Propharma Co., Ltd. (marketing authorization holder).
The addition of the new formulation to the company's product lineup of opioid analgesics will provide another treatment option to patients suffering from cancer pain and further enhance Daiichi-Sankyo's contribution to healthcare in Japan.
Are you a supplier?
Here's what CPhI Online can do for you
- Generate quality leads for your business
- Stay visible for 365 days of the year
- Receive product inquiries and respond to meeting requests directly
- Improve company online presence through Search Engine Optimisation